Management of post-menopausal osteoporosis: Something new on the horizon?

Journal of Endocrinological Investigation

Volumn 26, Issue 2, 2003, Pages 170-173

  Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bisphosphonates; Calcium; Estrogen; Menopause; Osteoporosis; Parathyroid hormone; Selective estrogen receptor modulators; Strontium; Vitamin D

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE REMODELING; CANCER RISK; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FRACTURE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 0037313957     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345147     Document Type: Review

References (17)

1. Consensus development conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 1993, 94: 646-650.
2. Faulkner K.G. Bone matters. Are density increases necessary to reduce fracture risks? J. Bone Miner. Res. 2000, 15: 183-187.
3. Guyatt G.H. Evidence-based management of patients with osteoporosis. J. Clin. Densitom. 1998, 1: 395-402.
4. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002, 288: 49-57.
5. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28: 524-531.
6. Schnitzer T., Bone H.G., Crepaldi G., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin. Exp. Res. 2000, 12: 1-12.
7. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2002, 346: 653-661.
8. Adami S., Delmas P., Felsenberg D., et al. Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Osteoporos. Int. 2002, 13: S14.
9. Lindsay R., Cosman F., Lobo R.A., et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial. J. Clin. Endocrinol. Metab. 1999, 84: 3076-3081.
10. Johnnell O., Scheele W.H., Reginster J.Y., Need A.G., Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 2002, 87: 985-992.
11. Harris S.T., Eriksen E.F., Davidson M., et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 2001, 86: 1890-1897.
12. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344: 1434-1441.
13. Meunier P.J., Slosman D.O., Delmas P.D., et al. Strontium ranelate: Dose-dependent effects in established post-menopausal vertebral osteoporosis-A 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 2002, 87: 2060-2066.
14. Meunier P.J., Roux C., Ortolani S., et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos. Int. 2002, 13: O45.
15. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metab. 2002, 87: 1586-1592.
16. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 2001, 22: 477-501.
17. Rittmaster R.S., Bolognese M., Ettinger M.P. et al., Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 2000, 85: 2129-2134.